Bristol-Myers Squibb Company ($BMY) Stock Forecast: Down 5.5% Today

What is Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company (BMY) is a pharmaceutical company known for its innovative drugs and treatments. The stock had a bearish movement today in the market.

Why is Bristol-Myers Squibb Company going down?

BMY stock is down 5.5% on Nov 14, 2025 14:42

• Despite strong performance in the third quarter, Bristol Myers Squibb experienced a bearish movement, possibly due to profit-taking by investors after a recent 7.2% increase in share price.
• Jim Cramer's decision to back off on Bristol-Myers might have influenced investor sentiment, leading to a sell-off in the stock.
• The market may be shifting focus towards other promising opportunities like Baidu and Alibaba, as mentioned by Jim Cramer, diverting attention away from Bristol-Myers Squibb in the short term.

BMY Price Chart

BMY Technical Analysis

BMY News

Jim Cramer Is Backing Off Bristol-Myers; Baidu, Alibaba Are Good - Alibaba Gr Hldgs ( NYSE:BABA ) , Baidu ( NASDAQ:BIDU )

On CNBC's "Mad Money Lightning Round," Jim Cramer said he is backing off on Bristol-Myers Squibb Company ( NYSE:BMY ) . On the earnings front, Bristol Myers Squibb, on Oct. 30, reported third-quarter 2025 revenues of $12.22 billion, beating the consensus of $11.81 billion, and a 3% increase ...

https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48777072/jim-cramer-is-backing-off-bristol-myers-but-these-2-chinese-stocks-are-good

Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?

Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.

https://www.zacks.com/stock/news/2788338/bristol-myers-gains-72-in-a-month-buy-sell-or-hold-the-stock

Trending Today

Bitcoin ($BTC) Crypto Forecast: Down 5.4% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 8.6% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 6.8% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 7.9% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Down 5.7% Today

Bristol-Myers Squibb Company Price History

01.09.2025 - BMY Stock was up 5.5%

• The bullish movement in BMY could be attributed to investors favoring its growth potential despite facing generic headwinds.
• The comparison with Merck (MRK) might have highlighted BMY's resilience and potential for future success, leading to increased investor confidence.
• The market's positive response indicates that BMY's strategic initiatives and focus on new treatments are resonating well with investors, driving the stock price higher.

14.10.2025 - BMY Stock was down 5.5%

• Despite strong performance in the third quarter, Bristol Myers Squibb experienced a bearish movement, possibly due to profit-taking by investors after a recent 7.2% increase in share price.
• Jim Cramer's decision to back off on Bristol-Myers might have influenced investor sentiment, leading to a sell-off in the stock.
• The market may be shifting focus towards other promising opportunities like Baidu and Alibaba, as mentioned by Jim Cramer, diverting attention away from Bristol-Myers Squibb in the short term.

25.06.2025 - BMY Stock was down 2.7%

• The stock of Bristol-Myers Squibb Inc. (BMY) experienced a strong bearish movement today.
• The disappointing news of Bristol Myers' drug, Reblozyl, failing in a blood cancer-associated anemia trial likely contributed to the bearish market movement.
• Investors may have reacted negatively to the drug's failure to meet the primary endpoint of 12-week RBC transfusion independence, impacting the stock price.
• The market sentiment could have been further dampened by the uncertainty surrounding the future prospects of Reblozyl and its potential impact on the company's revenue and growth trajectory.

30.09.2025 - BMY Stock was up 5.0%

• Investors are optimistic about BMY's upcoming Q3 earnings, expecting a boost from the rising demand for new therapies like Opdivo and Camzyos.
• The market movement reflects confidence in BMY's ability to navigate through declines in legacy-drug sales by focusing on its newer, more promising treatments.
• The bullish trend suggests that investors may be considering buying or holding BMY stock in anticipation of positive earnings results driven by the success of its innovative therapies.

30.09.2025 - BMY Stock was up 5.0%

• BMY saw a positive uptrend after surpassing Q3 earnings and sales expectations, boosted by the success of key drugs including Opdivo, Reblozyl, and Breyanzi.
• The decision to increase its 2025 sales forecast despite decreases in older drugs demonstrates confidence in its newer treatments and overall growth strategy.
• Market sentiment is favorable towards BMY's performance, especially as the growing demand for cutting-edge medications like Opdivo and Camzyos offsets declines in older products.

08.06.2025 - BMY Stock was up 2.6%

• BMY shares closed at $47.51, indicating a significant 2.64% increase from the previous trading session.
• Despite a slight drop earlier in the day, BMY managed to rally and outperform the market, showcasing resilience.
• The positive movement in BMY could be attributed to investor optimism surrounding the company's financial performance and potential growth prospects in the pharmaceutical sector.
• The overall bullish market sentiment likely provided further support to BMY's upward trajectory, as investors sought opportunities in stable and promising stocks like Bristol-Myers Squibb.

10.03.2025 - BMY Stock was down 6.1%

• The FDA approval for the label expansion of Opdivo plus Yervoy combo for colorectal cancer reflects positively on BMY, showcasing the company's dedication to addressing unmet medical needs.
• Despite this favorable development, the stock faced a bearish trend today, possibly due to investors taking profits, considering the approval had already been factored into the stock price.
• Investor apprehensions regarding the competitive environment in oncology or overall market conditions may have led to the sell-off of BMY shares, despite the encouraging regulatory update.
• Investors are advised to evaluate the long-term implications of BMY's extended label approval and its potential impact on the company's revenue and market standing in the oncology sector.

03.09.2025 - BMY Stock was down 5.0%

• BMY stock price dropped by 3.58% in the current session, continuing its downward trend over the past month and year.
• The Price Over Earnings overview indicates a decline in the stock's performance, possibly raising concerns among long-term shareholders.
• The bearish movement could be attributed to various factors such as disappointing earnings reports, regulatory setbacks, or broader market conditions impacting the pharmaceutical sector.

31.06.2025 - BMY Stock was down 5.6%

• Bristol-Myers Squibb (BMY) stock had a bearish movement today, potentially attributed to investors taking a cautious stance ahead of the company's Q2 earnings release.
• The expectations for BMY's Q2 results, where growth drugs are forecasted to offset some declines, may have caused uncertainty among investors, leading to the bearish trend.
• With the earnings report eagerly awaited, investors are likely adopting a "wait and see" strategy, adding to the downward pressure on BMY stock.
• While tech giants like Apple and Amazon are in the spotlight today, the pharmaceutical sector, represented by BMY, appears to be garnering a more subdued market reaction.

31.06.2025 - BMY Stock was down 5.9%

• Bristol-Myers Squibb posted Q2 revenue of $12.27 billion, exceeding expectations. However, their EPS of $1.46 missed the consensus of $1.58, leading to disappointment among investors.
• The company's decision to reduce the 2025 EPS guidance to $6.35-$6.65 could have influenced the market sentiment, despite an increase in the sales forecast to $46.5 billion-$47.5 billion.
• Uncertainties regarding the company's future performance, including the challenges of new product launches alongside declining legacy products, may be prompting investors to adopt a more cautious stance, resulting in the stock's downward trajectory on the latest trading day.

31.06.2025 - BMY Stock was down 5.4%

• BMY posted robust Q2 earnings and sales figures, surpassing expectations – typically prompting a bullish market response. However, missing EPS estimates and reducing the 2025 EPS guidance likely led to the bearish outlook.
• Uncertainty surrounding the company's future earnings potential may have triggered the negative market reaction, despite a positive sales forecast.
• Investors could be exercising caution due to conflicting analyst recommendations, with some advising to adopt a wait-and-see strategy before the Q2 results.
• The bearish movement in BMY's stock today might have been influenced by the overall market sentiment towards pharmaceutical stocks and broader economic conditions.

14.04.2025 - BMY Stock was down 5.1%

• The stock price of Bristol-Myers Squibb declined notably following the company's agreement to pay $350 million to the State of Hawaiʻi for resolving claims tied to the prescription drug Plavix. Such substantial legal settlements have the potential to impact a company's financial standing and influence investor confidence, contributing to the bearish market activity.
• Today's 1.20% drop in BMY shares may also be a result of investors reassessing the stock's price-to-earnings ratio. Given the recent stock price decrease over the past month and a history of fluctuations, investors may be realigning their positions, further fueling the prevailing bearish sentiment.
• Despite witnessing a positive upturn of 4.70% in the past year, the recent legal settlement and broader market conditions could have overshadowed this growth, culminating in the observed bearish trajectory today.